A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast

Investigator: Tejal Patel, MD

Study Coordinator: Lacey Burey

Status: Enrolling

ClinicalTrials.gov Number: NCT02032823

Phone: 713.441.1159

IRB Number: Pro00011594

Description

Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
More to Explore